Effect of Oral Donepezil on Intraocular Pressure in Normotensive Alzheimer Patients

Estermann, Stephan; Daepp, Gian-Carlo; Cattapan-Ludewig, Katja; Berkhoff, M.; Frueh, Béatrice E.; Goldblum, David

doi:10.1089/jop.2006.22.62

Cited by 16 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Topical rivastigmine lowered intraocular pressure (IOP) in rabbits (101). Oral administration of donepezil in normotensive Alzheimer patients resulted in decreased IOP and pupil diameter (102). A pilot study in normotensive glaucoma patients showed that donepezil improved visual field, ONH blood flow, regional cerebral blood flow, although IOP was not significantly changed.…”

Section: Visual System In Aging and Admentioning

confidence: 99%

At the interface of sensory and motor dysfunctions and Alzheimer's disease

Albers

Gilmore

Kaye

et al. 2014

Alzheimer's & Dementia

467

379

View full text Add to dashboard Cite

Recent evidence indicates that sensory and motor changes may precede the cognitive symptoms of Alzheimer’s disease (AD) by several years and may signify increased risk of developing AD. Traditionally, sensory and motor dysfunctions in aging and AD have been studied separately. To ascertain the evidence supporting the relationship between age-related changes in sensory and motor systems and the development of AD and to facilitate communication between several disciplines, the National Institute on Aging held an exploratory workshop titled “Sensory and Motor Dysfunctions in Aging and Alzheimer’s Disease”. The scientific sessions of the workshop focused on age-related and neuropathological changes in the olfactory, visual, auditory, and motor systems, followed by extensive discussion and hypothesis generation related to the possible links among sensory, cognitive, and motor domains in aging and AD. Based on the data presented and discussed at this workshop, it is clear that sensory and motor regions of the CNS are affected by Alzheimer pathology and that interventions targeting amelioration of sensory-motor deficits in AD may enhance patient function as AD progresses.

show abstract

Section: Visual System In Aging and Admentioning

confidence: 99%

At the interface of sensory and motor dysfunctions and Alzheimer's disease

Albers

Gilmore

Kaye

et al. 2014

Alzheimer's & Dementia

467

379

View full text Add to dashboard Cite

show abstract

“…Interestingly, in addition to its neuroprotective effects, a cholinesterase inhibitor used to treat AD has demonstrated dual therapeutic potential by reducing IOP in AD patients [155]. Current treatments for glaucoma are directed at reducing IOP, but evidence indicates that RGC loss still occurs in many glaucoma patients after successful IOP normalization, indicating that other mechanisms are involved.…”

Section: (Figure 7)mentioning

confidence: 99%

Ocular Biomarkers for Early Detection of Alzheimer's Disease

Frost

Martins

Kanagasingam

2010

JAD

View full text Add to dashboard Cite

Alzheimer's disease (AD) is the most common form of dementia and is characterized clinically by a progressive decline in memory, learning and executive function and neuropathologically by the presence of cerebral amyloid deposits. Despite a century of research, there is still no cure or conclusive pre-mortem diagnosis for the disease. A number of symptom-modifying drugs for AD have been developed, but their efficacy is minimal and short-lived. AD cognitive symptoms arise only after significant, irreversible neural deterioration has occurred, hence there is an urgent need to detect AD early, before the onset of cognitive symptoms. An accurate, early diagnostic test for AD would enable current and future treatments to be more effective, as well as contribute to the development of new treatments.While most AD related pathology occurs in the brain, the disease has also been reported to affect the eye, which is more accessible for imaging than the brain. AD-related proteins exist in the normal human eye and may produce ocular pathology in AD. There is some homology between the retinal and cerebral vasculatures and the retina also contains nerve cells and fibers that form a sensory extension of the brain. The eye is the only place in the body where vasculature or neural tissue is available for non-invasive optical imaging. This article presents a review of current literature on ocular morphology in AD and discusses the potential for an ocular based screening test for AD.

show abstract

“…An increased prevalence of POAG, which is open-angle glaucoma without exfoliations, in AD patients has been demonstrated by a few clinical studies (Bayer et al 2002a, b;Tamura et al 2006), while other studies have not found an association between POAG and AD (Estermann et al 2006;Kessing et al 2007). The conflicting data might in part be due to methodological issues, i.e., the criteria of glaucoma used, as reviewed recently (Kirby et al 2010).…”

Section: Introductionmentioning

confidence: 95%

No Association of LOXL1 Gene Polymorphisms with Alzheimer’s Disease

et al. 2011

View full text Add to dashboard Cite

Aggregation of amyloid-beta is one of the major characteristics in brains of patients with Alzheimer's disease (AD). Although several mechanisms behind the formation of such aggregates have been suggested the regulatory factors are still unknown. The present study aimed at investigating the association of lysyl oxidase-like 1 (LOXL1) polymorphisms with AD diagnosis and cerebrospinal fluid biomarkers (CSF) for the disease. Proteins of the lysyl oxidase (LOX) family are involved in cross-linking extracellular matrix proteins to insoluble fibers and have been associated with neurodegenerative diseases including AD. Genetic polymorphisms in LOXL1 (rs1048661, rs3825942, and rs2165241) have been linked to exfoliation syndrome and exfoliation glaucoma, conditions that have shown association with AD. The polymorphisms were genotyped by Taqman allelic discrimination in a study sample including AD patients (n = 318) and controls (n = 575). In a subgroup of the population, the polymorphisms were analyzed in relation to APOE ε4 genotype and to CSF (T-tau, P-tau, and Aβ(1-42)). No evidence for associations of these polymorphisms with risk for AD or any of the studied CSF biomarkers measured was found. These results do not support LOXL1 as being a major risk gene for AD.

show abstract

Effect of Oral Donepezil on Intraocular Pressure in Normotensive Alzheimer Patients

Cited by 16 publications

References 29 publications

At the interface of sensory and motor dysfunctions and Alzheimer's disease

At the interface of sensory and motor dysfunctions and Alzheimer's disease

Ocular Biomarkers for Early Detection of Alzheimer's Disease

No Association of LOXL1 Gene Polymorphisms with Alzheimer’s Disease

Contact Info

Product

Resources

About